Coherus Oncology, Inc.
Company Stats
- Market Cap
- $186.9M
- as of Sep 30, 2026
- Shares Outstanding
- 154.5M
- Free Float
- 83.9%
Income Statement
- Revenue
- $42.2M
- Operating Income
- -$181.1M
- Net Income
- $168.0M
- EBITDA
- -$179.8M
- Revenue Growth, 3Y
- -41.5%
Balance Sheet
- Cash & Equivalents
- $88.9M
Returns & Capital
- SBC, 3Y Avg
- $29.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $42.2M | — | — |
| FY2024 | $26.4M | — | — |
| FY2023 | $257.2M | -$175.2M | -68.1% |
| FY2022 | $211.0M | -$243.2M | -115.2% |
| FY2021 | $326.6M | -$38.7M | -11.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 31, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back